Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Updated . What changed?
C4 Therapeutics, Inc is an other business based in the US. C4 Therapeutics shares (CCCC) are listed on the NASDAQ and all prices are listed in US Dollars. C4 Therapeutics employs 88 staff and has a trailing 12-month revenue of around USD$33.1 million.
|52-week range||USD$19 - USD$48.975|
|50-day moving average||USD$39.4955|
|200-day moving average||USD$32.6005|
|Wall St. target price||USD$42.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$33.1 million|
|Gross profit TTM||USD$21.4 million|
|Return on assets TTM||0%|
|Return on equity TTM||0%|
|Market capitalisation||USD$1.8 billion|
TTM: trailing 12 months
There are currently 1.5 million C4 Therapeutics shares held short by investors – that's known as C4 Therapeutics's "short interest". This figure is 14.7% down from 1.8 million last month.
There are a few different ways that this level of interest in shorting C4 Therapeutics shares can be evaluated.
C4 Therapeutics's "short interest ratio" (SIR) is the quantity of C4 Therapeutics shares currently shorted divided by the average quantity of C4 Therapeutics shares traded daily (recently around 211824.75928473). C4 Therapeutics's SIR currently stands at 7.27. In other words for every 100,000 C4 Therapeutics shares traded daily on the market, roughly 7270 shares are currently held short.
To gain some more context, you can compare C4 Therapeutics's short interest ratio against those of similar companies.
However C4 Therapeutics's short interest can also be evaluated against the total number of C4 Therapeutics shares, or, against the total number of tradable C4 Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case C4 Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 C4 Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.0487% of the tradable shares (for every 100,000 tradable C4 Therapeutics shares, roughly 49 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against C4 Therapeutics.
Find out more about how you can short C4 Therapeutics stock.
We're not expecting C4 Therapeutics to pay a dividend over the next 12 months.
C4 Therapeutics, Inc., a biopharmaceutical company, develops novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable degrader targeting IKZF1/3 for multiple myeloma, peripheral T-cell lymphoma, and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid malignancies; and BRAF V600E and RET programs for genetically defined resistant solid tumors. It has strategic collaborations with F. Hoffman-La Roche Ltd.; Biogen, Inc.; and Calico Life Sciences LLC. C4 Therapeutics, Inc. was founded in 2015 and is headquartered in Watertown, Massachusetts.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.